Opinion|Videos|March 21, 2025
Mechanism of Action Differences Among IL-17 Inhibitors
Panelists discuss how IL-17 inhibitors differ in their targets within the IL-17 pathway. Secukinumab and ixekizumab block IL-17A, reducing inflammation in psoriasis and arthritis. Brodalumab inhibits IL-17RA, affecting multiple IL-17 cytokines, but carries suicide risk warnings. Bimekizumab targets IL-17A and IL-17F, potentially enhancing efficacy but with added risk of infections. These differences impact efficacy, safety, and patient selection in inflammatory diseases.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do the mechanisms of action of the approved IL-17 inhibitors differ from one another, and how might these differences translate in terms of efficacy and/or safety?
- Secukinumab (IL-17A inhibitor)—approved 2015
- Ixekizumab (IL-17A inhibitor)—approved 2016
- Brodalumab (IL-17RA inhibitor)—approved 2017
- Bimekizumab (IL-17A and IL-17F inhibitor)—approved 2023
Advertisement
Related to this article
BE BOLD Week 24 data show sustained numerical advantages in joint responses with bimekizumab versus risankizumab in active psoriatic arthritis.
Doral Fredericks, PharmD, MBA, discusses how life stages, mental health, and reproductive concerns can shape dermatologic care for women.
The approval expands the IL-23 inhibitor’s indications beyond moderate-to-severe plaque psoriasis to include adults with active psoriatic arthritis.
Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.
Experts outline how to recognize undertreated psoriasis, assess incomplete response, and make individualized decisions when escalating therapy.
ORKA-001 achieved PASI 100 in 61% of high-dose patients at week 16 in the phase 2b EVERLAST-B trial of moderate-to-severe psoriasis.
Tina Bhutani-Jacques, MD, explored how disease location, prior treatment response, and patient preference shape topical treatment decisions across 3 plaque psoriasis cases.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
Advertisement
Advertisement
Trending on Dermatology Times
1
Don't Be Rash: Navigating Topical Steroid Withdrawal Concerns in Pediatric Eczema
2
AADA Warns of 6% Medicare Payment Cut for Dermatologists in 2027
3
ATTO-1310 Reduces Itch at Week 12 in Chronic Pruritus and Atopic Dermatitis
4
Where Patients With Alopecia Areata Fit on the Path to Systemic Treatment
5